Recent Advances in Pulmonary Hypertension: Diagnosis and Treatment
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 111
Special Issue Editors
Interests: pulmonary thromboembolism; pulmonary hypertension; shock
Special Issues, Collections and Topics in MDPI journals
Interests: pulmonary embolism; angioplasty; endovascular intervention
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pulmonary hypertension remains a major cause of morbidity and mortality worldwide. Advances seen over the past decade have substantially improved outcomes in patients with pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease, but many patients remain at high risk of clinical deterioration.
In this Special Issue, we will highlight major recent developments in the treatment of PAH, including the addition of sotatercept as a disease-modifying therapy, and discuss the impact of the most recent World Symposium on Pulmonary Hypertension 2024 guidelines on the management of PAH. This Special Issue will also highlight challenges in patients who have PH associated with interstitial lung disease and chronic obstructive pulmonary disease, as well as the unique challenges associated with PH due to heart failure with preserved ejection fraction. We welcome both narrative and structured reviews, as well as original research articles, addressing these areas.
Dr. Yuri Matusov
Dr. Suhail Dohad
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary hypertension
- PH-ILD
- interstitial lung disease
- right ventricular failure
- PH-COPD
- HFpEF-PH
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
